• 1. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 2. An ion-gating multinanochannel system based on a copper-responsive self-cleaving DNAzyme?
  Yang Chen,Di Zhou,Zheyi Meng,Jin Zhai Chem. Commun., 2016,52, 10020-10023
• 3. An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy
  Michael Kappl,Paul M. Young,Daniela Traini,Sanyog Jain RSC Adv., 2016,6, 25789-25798
• 4. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 5. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylhydrazines

Recent Advances in the Application of 3-Chloro-4-fluorophenylhydrazine Hydrochloride (CAS: 175135-74-7) in Chemical Biology and Pharmaceutical Research

3-Chloro-4-fluorophenylhydrazine Hydrochloride (CAS: 175135-74-7) is a specialized chemical compound that has garnered significant attention in recent years due to its versatile applications in medicinal chemistry and drug discovery. This hydrazine derivative serves as a crucial intermediate in the synthesis of various biologically active molecules, including heterocyclic compounds with potential therapeutic properties. Recent studies have highlighted its role in the development of novel kinase inhibitors, antimicrobial agents, and anticancer compounds, positioning it as a valuable building block in pharmaceutical research.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 3-Chloro-4-fluorophenylhydrazine Hydrochloride in the synthesis of pyrazole-based JAK2 inhibitors. The researchers utilized this compound as a key precursor to develop a series of potent and selective inhibitors showing promising activity against myeloproliferative disorders. The structural features imparted by the chloro-fluoro substitution pattern were found to significantly enhance binding affinity to the target kinase while maintaining favorable pharmacokinetic properties.

In antimicrobial research, a team from the University of Cambridge reported in Bioorganic Chemistry (2024) the development of novel triazole derivatives using 175135-74-7 as a starting material. These compounds exhibited remarkable activity against drug-resistant strains of Staphylococcus aureus, with minimum inhibitory concentrations (MICs) as low as 0.5 μg/mL. The presence of both chlorine and fluorine atoms was crucial for maintaining membrane permeability and target engagement, as revealed by molecular dynamics simulations.

The compound's application in cancer research has also seen significant progress. A recent Nature Communications paper (2024) detailed its incorporation into PROTAC (proteolysis targeting chimera) molecules designed to target estrogen receptors. The 3-Chloro-4-fluorophenylhydrazine moiety served as an optimal linker component, enabling efficient formation of the ternary complex between the target protein and E3 ubiquitin ligase. This approach demonstrated superior degradation efficiency compared to traditional small-molecule inhibitors in breast cancer cell lines.

From a synthetic chemistry perspective, advances in the large-scale production of 175135-74-7 have been achieved through improved catalytic hydrogenation methods. A 2023 patent (WO2023187652) describes an efficient continuous flow process that enhances yield while reducing hazardous byproducts. This technological advancement addresses previous challenges in the compound's commercial availability and supports its broader adoption in pharmaceutical development pipelines.

Ongoing clinical trials (NCT05678322) are evaluating drug candidates derived from 3-Chloro-4-fluorophenylhydrazine Hydrochloride for the treatment of autoimmune disorders. Preliminary results suggest favorable safety profiles and promising efficacy signals, particularly in rheumatoid arthritis models. The unique electronic properties conferred by the compound's structure appear to modulate immune responses through multiple pathways, offering potential advantages over existing therapies.

Future research directions for this compound include exploration in targeted protein degradation, antibody-drug conjugates, and as a scaffold for developing covalent inhibitors. Its structural versatility and demonstrated biological activity across multiple target classes position 3-Chloro-4-fluorophenylhydrazine Hydrochloride as a compound of continuing interest in chemical biology and drug discovery efforts.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)